Why the study?
Does androgen-deprivation therapy increase cardiovascular disease risk factors in African men with prostate cancer?
Does androgen-deprivation therapy increase cardiovascular disease risk factors in African men with prostate cancer?
Androgen-deprivation therapy in African men with prostate cancer is associated with elevated cardiovascular risk factors, highlighting the need for cardiovascular screening in this population.
Supports CV monitoring during ADT in African men; hypothesis-generating for causal effects on events.
PURPOSE: Cardiovascular disease risk factors have been associated with androgen-deprivation therapy (ADT) in white and Hispanic populations. It is therefore relevant to determine if there exists a relationship between these parameters in the African population. PATIENTS AND METHODS: The design of the study was cross sectional. Prostate-specific antigen concentration, waist circumference, body mass index (BMI), lipid profile, glucose level, and insulin level were determined in 153 patients with prostate cancer and 80 controls. The patients with prostate cancer were divided into subgroups of treatment-naïve patients and those receiving ADT. RESULTS: = .029) values were significantly higher in patients treated with ADT when compared with treatment-naïve patients. In patients treated with ADT for up to 1 year, only mean BMI was significantly higher than in treatment-naïve patients, whereas those treated with ADT for more than 1 year had significantly higher mean BMI, waist circumference, total cholesterol, and LDL cholesterol values when compared with treatment-naïve patients. There were no significant differences in insulin or glucose levels. Those undergoing hormone manipulation after orchiectomy had fewer cardiovascular risk factors compared with those undergoing hormone manipulation alone. CONCLUSION: This study shows that ADT results in elevated total cholesterol, LDL cholesterol, BMI, and waist circumference values, all of which are risk factors of cardiovascular disease. Screening for cardiovascular risk factors should be included in treatment plans for patients with prostate cancer.
No takes yet. Share an insight, caveat, or question.
Essien et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: